Federal Register / Vol. 74, No. 188 / Wednesday, September 30, 2009 / Notices 50211 

Federal Maritime Commission an 

application for license as a Non-VesselOperating Common Carrier and Ocean 

Freight Forwarder—Ocean 

Transportation Intermediary pursuant to 

section 19 of the Shipping Act of 1984 

as amended (46 U.S.C. Chapter 409 and 

46 CFR part 515). 

Persons knowing of any reason why 

the following applicants should not 

receive a license are requested to 

contact the Office of Transportation 

Intermediaries, Federal Maritime 

Commission, Washington, DC 20573. 

Non-Vessel-Operating Common Carrier 

Ocean Transportation Intermediary 

Applicants 

Avango Logistics LLC, 552 N York Road, 

Bensenville, IL 60106, Officers: 

Konstantin B. Selikhov, Member 

(Qualifying Individual), Rostislav 

Chagovets, Member. 

Non-Vessel-Operating Common Carrier 

and Ocean Freight Forwarder 

Transportation Intermediary 

Applicants 

HYH International Cargo Services, Inc., 

dba H.Y.H. Container Line, 9107 NW 

105th Way, Medley, FL 33178, 

Officer: Hans G. Hofmann, President 

(Qualifying Individual). 

Ocean Star International, Inc., 10880 

Wiles Road, Coral Springs, FL 33078, 

Officer: Joshua S. Morales, President 

(Qualifying Individual). 

Container Loading Solutions 

International USA, LLC, 755 North 

Busse Highway, Ste. 217, Bensenville, 

IL 60106, Officer: Paul J. Gibbs, 

President (Qualifying Individual). 

Fleur De Lis Worldwide LLC, 8302 

Shady Ace Lane, Humble, TX 77346, 

Officer: Julie A. Turpin, President 

(Qualifying Individual). 

Consolcargo USA Inc. dba CSC 

Consolidators, 10925 NW 27th Street, 

Ste. 102, Miami, FL 33172, Officers: 

Rocio D. Lugo, Director (Qualifying 

Individual), Peter Thomas, Vice 

President. 

A Cargo Inc., 4634 E. Marginal Way S., 

Ste. C–120, Seattle, WA 98134–2328, 

Officers: Marcio Fanti, President, 

Patrick P. Policarpio, Vice President 

(Qualifying Individuals). 

DNIPRO LLC, 645 West 1st Avenue, 

Roselle, NJ 07203, Officers: Yelena 

Cherepashenskaya, Manager 

(Qualifying Individual), Igor Pluta, 

President. 

Target Logistic Services, Inc., 1400 

Glenn Curtiss Street, Carson, CA 

90746, Officer: Thomas F. Donahue, 

III, Vice President (Qualifying 

Individual). 

Ocean Freight Forwarder—Ocean 

Transportation Intermediary 

Applicants 

EP Logistics, LLC, 7 Founders Blvd., 

Ste. E, El Paso, TX 79906, Officer: 

Octavio Saavedra, Member 

(Qualifying Individual). 

Concord Express Cargo, Inc., 172–14 

119th Avenue, Jamaica Queens, NY 

11434, Officers: Christopher E. 

Okafor, President (Qualifying 

Individual), Margaret X. Burnes, 

Secretary. 

September 25, 2009. 

Tanga S. FitzGibbon, 

Assistant Secretary. 

[FR Doc. E9–23568 Filed 9–29–09; 8:45 am] 

BILLING CODE 6730–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the National Coordinator for 

Health Information Technology 

HIT Policy Committee Advisory 

Meeting; Notice of Two-Day Meeting 

AGENCY: Office of the National 

Coordinator for Health Information 

Technology, HHS. 

ACTION: Notice of meeting. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Office of the National Coordinator 

for Health Information Technology 

(ONC). The meeting will be open to the 

public. 

Name of Committee: HIT Policy 

Committee. 

General Function of the Committee: 

To provide recommendations to the 

National Coordinator on a policy 

framework for the development and 

adoption of a nationwide health 

information technology infrastructure 

that permits the electronic exchange and 

use of health information as is 

consistent with the Federal Health IT 

Strategic Plan and that includes 

recommendations on the areas in which 

standards, implementation 

specifications, and certification criteria 

are needed. 

Date and Time: The two-day meeting 

will be held on October 27 and October 

28, 2009, from 10 a.m. to 5:15 p.m./ 

Eastern Time on October 27th, and 8:30 

a.m. to 3 p.m./Eastern Time on October 

28th. 

Location: The Omni Shoreham Hotel, 

2500 Calvert Street, NW., Washington, 

DC. The hotel telephone number is 202– 

234–0700. 

Contact Person: Judy Sparrow, Office 

of the National Coordinator, HHS, 330 C 

Street, SW., Washington, DC 20201, 

202–205–4528, Fax: 202–690–6079, email: judy.sparrow@hhs.gov. Please call 

the contact person for up-to-date 

information on this meeting. A notice in 

the Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Agenda: The committee will hear 

presentations from the Meaningful Use, 

Certification/Adoption, and Information 

Exchange Workgroups. In addition, 

invited experts will provide testimony 

on the mapping of core Meaningful Use 

objectives and existing measures to 

medical specialties, small practices, and 

small hospitals. ONC intends to make 

background material available to the 

public no later than two (2) business 

days prior to the meeting. If ONC is 

unable to post the background material 

on its Web site prior to the meeting, it 

will be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posed on ONC’s Web site after 

the meeting, at http://healthit.hhs.gov. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before October 18, 2009. 

Oral comments from the pubic will be 

scheduled approximately 5 p.m./Eastern 

Time on October 27th, and 12:30 p.m./ 

Eastern Time on October 28th. Time 

allotted for each public comment is 

limited to two minutes. If the number of 

speakers requesting to comment is 

greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, ONC will 

take written comments after the meeting 

until close of business. 

Persons attending ONC’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

ONC welcomes the attendance of the 

public at its advisory committee 

meetings. Seating is limited at the 

location, and ONC will make every 

effort to accommodate persons with 

physical disabilities or special needs. If 

you require special accommodations 

due to a disability, please contact Judy 

Sparrow at least seven (7) days in 

advance of the meeting. 

ONC is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://healthit.hhs.gov for procedures 

on public conduct during advisory 

committee meetings. 


CPrice-Sewell on DSKGBLS3C1PROD with NOTICES
50212 Federal Register / Vol. 74, No. 188 / Wednesday, September 30, 2009 / Notices 

Notice of this meeting is given under 

the Federal Advisory Committee Act 

(Pub. L. 92–463, 5 U.S.C., App. 2). 

Dated: September 24, 2009. 

Judith Sparrow, 

Office of Programs and Coordination, Office 

of the National Coordinator for Health 

Information Technology. 

[FR Doc. E9–23460 Filed 9–29–09; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Toxicology Program (NTP); 

NTP Interagency Center for the 

Evaluation of Alternative Toxicological 

Methods (NICEATM); Availability of the 

Interagency Coordinating Committee 

on the Validation of Alternative 

Methods (ICCVAM) Test Method 

Evaluation Report: The Reduced 

Murine Local Lymph Node Assay, an 

Alternative Test Method Using Fewer 

Animals To Assess the Allergic 

Contact Dermatitis Potential of 

Chemicals and Products; Availability 

of ICCVAM Recommended Murine 

Local Lymph Node Assay Performance 

Standards; Notice of Transmittal to 

Federal Agencies of ICCVAM Test 

Method Recommendations for the 

Reduced Murine Local Lymph Node 

Assay, Updated Murine Local Lymph 

Node Assay Test Method Protocol, and 

Murine Local Lymph Node Assay Test 

Method Performance Standards 

AGENCY: National Institute of 

Environmental Health Sciences 

(NIEHS), National Institutes of Health 

(NIH) 

ACTION: Availability of ICCVAM Test 

Method Evaluation Report (TMER) and 

Recommended Test Method 

Performance Standards; Notice of 

Transmittal. 

SUMMARY: NICEATM announces 

availability of the ICCVAM Test Method 

Evaluation Report: The Reduced Murine 

Local Lymph Node Assay: An 

Alternative Test Method Using Fewer 

Animals to Assess the Allergic Contact 

Dermatitis Potential of Chemicals and 

Products (NIH Publication 09–6439). 

The TMER provides ICCVAM’s 

evaluation and recommendations for the 

reduced Murine Local Lymph Node 

Assay (rLLNA) test method as a 

reduction alternative that uses fewer 

animals compared to the traditional 

Murine Local Lymph Node Assay 

(LLNA) for assessing the potential of test 

substances to cause allergic contact 

dermatitis (ACD). The report includes 

ICCVAM’s recommendations on (a) the 

usefulness and limitations of the 

rLLNA, (b) an updated ICCVAM LLNA 

test method protocol, which includes 

the procedures for conducting the 

rLLNA, (c) future studies to further 

characterize the usefulness and 

limitations of the rLLNA, and (d) rLLNA 

test method performance standards. The 

TMER includes the report of an 

international independent scientific 

peer review panel (hereafter, Panel) and 

the final rLLNA background review 

document (BRD). The BRD provides the 

data and analyses used to evaluate the 

current validation status of the rLLNA 

test method for assessing the ACD 

potential of chemicals and products. 

ICCVAM concluded that the scientific 

validity of the rLLNA has been 

adequately evaluated and that the 

performance of the rLLNA, when 

conducted in accordance with the 

ICCVAM-recommended LLNA test 

method protocol, is sufficient to 

distinguish between skin sensitizers and 

non-sensitizers. ICCVAM also 

concluded that the rLLNA would reduce 

animal use by 40% for each test 

compared to the traditional, multi-dose 

LLNA. Accordingly, ICCVAM 

recommends that the rLLNA test 

method should be routinely considered 

before conducting the traditional, multidose LLNA, and used where appropriate 

as the initial test to determine the 

potential of chemicals and products to 

produce ACD. For testing situations that 

require dose-response information, 

rLLNA-positive substances will need to 

be tested with the traditional multi-dose 

LLNA. This testing should be done 

using the updated ICCVAMrecommended test method protocol, 

which reduces animal use by 20% 

compared to the original ICCVAMrecommended test method protocol by 

decreasing the minimum number of 

animals per dose group from five to 

four. 

NICEATM also announces availability 

of the ICCVAM Recommended 

Performance Standards: Murine Local 

Lymph Node Assay (NIH Publication 

09–7357). The ICCVAM recommends 

that LLNA test method performance 

standards can be used to efficiently 

evaluate the validity of modified 

versions of the LLNA that are 

mechanistically and functionally similar 

to the traditional LLNA. The traditional 

LLNA test method is the reference test 

method used as the basis for 

establishing the LLNA performance 

standards. The performance standards 

specify the essential test method 

components that must be included in a 

modified LLNA in order to use the 

performance standards to evaluate the 

validity of the modified test method. 

The performance standards also specify 

a minimum list of reference substances 

to evaluate the accuracy and reliability 

of the modified test method, and the 

accuracy and reliability values that must 

be achieved in order for the modified 

test method to be considered equal to or 

better than the traditional LLNA. 

Electronic copies of the ICCVAM 

rLLNA TMER and the report on 

ICCVAM-recommended LLNA 

performance standards are available 

from the NICEATM–ICCVAM Web site 

at http://iccvam.niehs.nih.gov or by 

contacting NICEATM (see FOR FURTHER

INFORMATION CONTACT). The two reports 

have been forwarded to U.S. Federal 

agencies for regulatory and other 

acceptance considerations, where 

applicable. Responses will be posted on 

the NICEATM–ICCVAM website as they 

are received. 

FOR FURTHER INFORMATION CONTACT: Dr. 

William S. Stokes, Director, NICEATM, 

NIEHS, P.O. Box 12233, Mail Stop: K2– 

16, Research Triangle Park, NC 27709, 

(telephone) 919–541–2384, (fax) 919– 

541–0947, (e-mail) 

niceatm@niehs.nih.gov. Courier address: 

NICEATM, NIEHS, Room 2034, 530 

Davis Drive, Morrisville, NC 27560. 

SUPPLEMENTARY INFORMATION: 

Background 

The U.S. Consumer Product Safety 

Commission (CPSC) nominated several 

new versions and applications of the 

LLNA to ICCVAM in 2007 for 

evaluation of their scientific validity 

(http://iccvam.niehs.nih.gov/methods/ 

immunotox/llnadocs/ 

CPSC_LLNA_nom.pdf). The nomination 

requested that ICCVAM assess the 

validation status of: (1) the LLNA limit 

dose procedure (i.e., the rLLNA); (2) 

three modified LLNA test method 

protocols that do not require the use of 

radioactive materials; (3) the use of the 

LLNA to test mixtures, aqueous 

solutions, and metals (applicability 

domain for the LLNA); and (4) the use 

of the LLNA to determine ACD potency 

categories for hazard classification. 

NICEATM published a Federal Register 

notice (72 FR 27815) requesting public 

comments on the appropriateness and 

relative priority of the CPSC-nominated 

LLNA activities, the development of test 

method performance standards for the 

LLNA, the nomination of scientists to 

serve on the Panel, and the submission 

of data from LLNA testing that related 

to the CPSC-nominated LLNA activities, 

as well as corresponding data from 

human and other animal studies. After 

considering public comments and 

comments from the Scientific Advisory 

Committee on Alternative Toxicological 


CPrice-Sewell on DSKGBLS3C1PROD with NOTICES